Aspen Neuroscience announced it has expanded its current good manufacturing practice (cGMP) facilities in San Diego to increase capacity for its personalized cell therapy programs. According to the company, the additional space will support ongoing clinical trials and potential future commercial production.
The company said the new facility includes upgraded manufacturing suites designed to produce autologous neuron replacement therapies derived from patients’ own induced pluripotent stem cells (iPSCs). Aspen Neuroscience claims this expansion will help advance its lead candidate, ANPD001, currently being evaluated in a Phase 1/2a clinical trial for Parkinson’s disease.
Aspen Neuroscience also said the expanded capacity aligns with its fully integrated model, which combines patient biopsy processing, iPSC reprogramming, manufacturing, quality control, and release testing under one roof. The company claims this approach is intended to streamline development and reduce production timelines for personalized cell therapies.
According to the company, the new space is now operational and staffed by its existing cell therapy manufacturing and quality teams. Aspen Neuroscience claims the facility reflects its long-term strategy to establish in-house expertise and infrastructure to scale autologous regenerative treatments.
